Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBPP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Regen BioPharma (RGBPP) over the last 13 years, with Q3 2025 value amounting to $182421.0.

  • Regen BioPharma's Operating Expenses rose 2600.92% to $182421.0 in Q3 2025 from the same period last year, while for Dec 2025 it was $454656.0, marking a year-over-year decrease of 2324.89%. This contributed to the annual value of $575101.0 for FY2025, which is 1203.46% down from last year.
  • As of Q3 2025, Regen BioPharma's Operating Expenses stood at $182421.0, which was up 2600.92% from $99821.0 recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's Operating Expenses peaked at $522931.0 during Q4 2022, and registered a low of $40398.0 during Q1 2021.
  • Over the past 5 years, Regen BioPharma's median Operating Expenses value was $144768.0 (recorded in 2024), while the average stood at $160714.2.
  • In the last 5 years, Regen BioPharma's Operating Expenses skyrocketed by 29999.79% in 2021 and then tumbled by 6522.54% in 2023.
  • Over the past 5 years, Regen BioPharma's Operating Expenses (Quarter) stood at $165487.0 in 2021, then skyrocketed by 216.0% to $522931.0 in 2022, then plummeted by 65.23% to $181847.0 in 2023, then crashed by 33.77% to $120443.0 in 2024, then soared by 51.46% to $182421.0 in 2025.
  • Its Operating Expenses was $182421.0 in Q3 2025, compared to $99821.0 in Q2 2025 and $172414.0 in Q1 2025.